ArticleNanomedicine (London, England)2025
Affinity-driven functionalization of magnetic nanoparticles using tryptophan-isatin for potential bio-applications.
Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study aims to develop biocompatible magnetic nanoparticles (MNPs) functionalized with tryptophan (Trp) and isatin (Isa), two biologically active molecules with known blood-brain barrier permeability and anticancer activity. The primary objective was to evaluate the potential of these functionalized MNPs for glioblastoma therapy.
methodsTrp and Isa were conjugated onto MNPs, and the resulting nanomaterials were characterized using SEM-EDS, FTIR, XPS, and DLS. The U-87 human glioblastoma cell line was used to investigate cellular uptake, cytotoxicity (MTT assay), and radiosensitizing effects. Additional molecular insights were obtained through STRING-based network analysis.
resultsThe synthesized MNPs exhibited spherical morphology with a uniform size of approximately 100-110 nm. No significant cytotoxicity was observed at concentrations up to 10 µg/mL under standard culture conditions. However, a 70% reduction in cell viability was achieved following radiotherapy when cells were pretreated with Trp-Isa functionalized MNPs. STRING analysis revealed that Trp and Isa are involved in molecular pathways associated with glioblastoma.
conclusionThese findings suggest that Trp and Isa functionalized MNPs hold promise as a targeted and radiosensitizing nanoplatform for glioblastoma treatment. The approach also highlights broader potential for such engineered nanoparticles in the field of nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.